Navigation Links
Celsis Receives Frost & Sullivan 2008 Best Practices Award

CHICAGO, Oct. 1 /PRNewswire/ -- Celsis Rapid Detection, a division of Celsis International plc (LSE: CEL.L), has been named the Frost & Sullivan 2008 North American Growth Strategy Leadership Award recipient for Rapid Microbial Testing Methods used in the Manufacture and Release of Pharmaceuticals.

"The Celsis Rapid Detection system is a powerful and flexible technology that enables pharmaceutical companies to significantly reduce production cycle times in the manufacturing process," said Madhu Sharma, Ph.D, industry analyst for Frost & Sullivan. "Not only does Celsis help customers get safe products to market faster, it returns bottom-line benefits like freed-up working capital while reducing inventory and safety stock requirements."

Conventional screening for microbial contamination in raw materials, in-process work or finished goods takes an average of five days at each step. Through the use of a proprietary enzyme accelerant, the Celsis system delivers an accurate verdict in as little as 18 hours, allowing companies to run leaner and more responsive manufacturing systems.

"We are very pleased to be recognized for our leadership in rapid testing methods for pharmaceutical manufacturers," explained Jay LeCoque, Celsis CEO. "Our customers are strong advocates of rapid methods because of the highly reliable Celsis system, our world-class service, and the simple fact that we save them significant time and money by taking days out of their manufacturing cycle times."

Frost & Sullivan selected Celsis as a Best Practices Award recipient in the 2008 North American Growth Strategy Leadership category for the company's focused efforts in product innovation, sales strategy, and customer support. The research and growth consulting firm also recognized Celsis' ability to increase the market presence, regulatory acceptance, and widespread adoption of its Celsis Rapid Detection systems.

Celsis Model Identifies ROI in Advance

Frost & Sullivan cited the company's unique financial tool, the Value Creation Model (VCM), as a key initiative driving Celsis' growth. Designed in collaboration with consulting firm Arthur D. Little, Inc., the VCM calculates the financial return from implementing the Celsis system for rapid microbiological testing. According to Celsis customer data, adopters of the system see an average return on investment in six to nine months with a five-year net present value (NPV) of $500,000 for a single plant. These strong results, forecast by the VCM, encourage new customers to adopt the technology, and the tool has paved the way for Celsis to advance to the top of the market.

Additionally, as noted by Frost & Sullivan, the Celsis system is extremely flexible, the workflow is easy to learn, and the instruments and software are standardized, making it attractive to customers with multiple manufacturing facilities or various types of products. Also attractive is the company's active research and development: Celsis is devising next-generation nucleic acid technologies to position itself for long-term growth.

For more information about the Celsis system, visit, where there is a link to a free whitepaper and an online "lite" version of the Value Creation Model called the Rapid Returns calculator. Frost & Sullivan Leadership Award information is available online at

About Celsis International plc

Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis division delivers significant time and cost savings to its customers in addition to ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's leading pharmaceutical and consumer products companies. Public since 1993, Celsis is headquartered in Chicago and listed on the London Stock Exchange (CEL.L).

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit

SOURCE Celsis International plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
(Date:11/24/2015)... - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" ... , President and Chief Executive Officer of ProMetic, will be ... th Annual Healthcare Conference to be held at the ... st , at 8.50am (ET) and ProMetic,s management team ... presentation will be available live via a webcast accessible at ...
(Date:11/24/2015)... ... ... Whitehouse Laboratories is pleased to announce that it has completed construction on a ... basic USP 61, USP 62 and USP 51 testing specific to raw materials and ... testing performed by one supplier. Management has formally announced that the facility ...
(Date:11/23/2015)... , ... November 23, 2015 , ... ... for the development of its Nexera UC Unified Chromatography system. The award from ... technically significant new products of the year in the analytical and testing category. ...
(Date:11/23/2015)... , Nov. 23, 2015  CryoLife, Inc. (NYSE: CRY ... on cardiac and vascular surgery, announced today that it will ... Healthcare Conference on Wednesday, December 2, 2015 at The New ... . Pat Mackin , President and Chief Executive ... Chief Executive Officer. --> A live webcast ...
Breaking Biology Technology:
(Date:11/18/2015)... 18, 2015 --> ... new market report titled  Gesture Recognition Market - Global ... - 2021. According to the report, the global gesture recognition market was ... to reach US$29.1 bn by 2021, at a CAGR ... North America dominated the global gesture recognition ...
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
Breaking Biology News(10 mins):